READING, Pa., March 28, 2023 /PRNewswire/ -- PharmaForce International (PFI) recently published a report in December that benchmarked the leading Immunology sales and marketing organizations in the United States. This report focused on the key companies with products competing across the Dermatology, Gastroenterology, and Rheumatology markets throughout 2022. In addition to those three therapeutic areas of focus, the Respiratory space has also become a key area of interest. Many profiled companies have started to promote Respiratory products under their Immunology divisions.
PharmaForce International: Benchmarking Report Captures the Digital Marketing Trends of Key Oncology and Immunology Companies
PharmaForce International (PFI) recently published a competitive intelligence report benchmarking the commercial operations and marketing...
PharmaForce International (PFI) recently completed a study that benchmarks the leading Oncology/Hematology/Immuno-Oncology sales and marketing organizations in five major European countries. The report profiles key companies and products competing within the ever-changing market in France, Germany, Italy, Spain, and the United Kingdom. Since the last report, which was published in June 2020, there have been notable trends taking place in the EU5 Oncology space.
READING, Pa., Oct. 6, 2020 /PRNewswire/ -- PharmaForce International (PFI) recently completed a 2020 report that benchmarks the leading oncology sales and marketing organizations in France, Germany, Italy, Spain, and the United Kingdom.
Pharmaforce’s Generic Floxuridine Receives Approval In US
Pharmaforce Generic Dexmedetomidine Hydrochloride Receives Approval In US